First publication of the COGNITION trial with breast cancer symples before and after NACT. Interestingly, there are not too many shifts as the mutagenic pressure of polychemotherapy seams limited and somehow restricted to hormone receptor positive disease. esmoopen.com/article/S2059-…

Six riddles for precision oncology! Riddle #2: When is a deleterious mutation pathogenic? Corollary: since “driver” mutations are found in non-malignant disease (arthritis, endometriosis, Alzheimer’s), can we repurpose cancer targeted drugs for these illnesses?

Comprehensive molecular profiling to inform clinical decision making in #AYA #sarcomas is feasible in a European setting. Great team effort under the auspices of EORTC, led by Marie Morfouace, Martin McCabe, NCT Heidelberg, Translational Medical Oncology & DKFZ. doi.org/10.1016/j.ejca…

Tolle Möglichkeit die translationale Krebsforschung im DKTK zu unterstützen und aktiv mitzugestalten. Wir suchen Sie als Wissenschaftliche:n Koordinator:in (m/w/d) u. freuen uns über Ihre Bewerbung. Infos: tinyurl.com/JobDKTK #job #gerne_weitersagen #dkfz #dktk VomLaborInDiePraxis DKFZ

In 1862 Charles Darwin received a flower from Madagascar with the nectar located in an extremely deep crevasse. He predicted the existence of a moth with an extraordinarily long tongue to reach the nectar. Xanthopan morganii was discovered 150 years later ow.ly/3hmm50B6Brz

CAPItello-291 phase 3 trial brings a new agent to the clinic. Adding the Akt-inhibitor capivasertib to fulvestrant doubled PFS (7.2 vs 3.6 months), with most benefit in AKT pathway-altered pts, but potential benefit also in wild type. Main AE: diarrhea (72%) & rash (39%).#SABCS22

Excited and happy about this early Christmas gift!🎄 Our article inspired the cover (entitled: “Riddle me this!”) for 2023’s 1st issue of Nature Reviews Cancer The extraordinary design was inspired and conceived by derHolle and redrawn by David Johnston! nature.com/nrc/volumes/23…

Excited and happy about this early Christmas gift!🎄 Our article inspired the cover (entitled: “Riddle me this!”) for 2023’s 1st issue of Nature Reviews Cancer The extraordinary design was inspired and conceived by derHolle and redrawn by David Johnston! nature.com/nrc/volumes/23…

Our Jan issue, out NOW! With articles on intravital imaging to study #metastasis, replication stress responses to optimize #therapy & the 6 riddles in precision oncology! Plus a Comment on using #SoMe for patient-driven #cancer research! 💌 go.nature.com/3We2WKi @natrescancer pic.x.com/xaujpeg8cl

Check out this Perspective! Adam Wahida, MD-PhD Razelle Kurzrock, MD Lars Buschhorn Stefan Fröhling Jost Laboratory on Molecular Oncology & colleagues present the six key riddles that must be solved to optimize the application of #precisiononcology to otherwise lethal malignancies. go.nature.com/3VIYYbo Cancer at Nature Portfolio pic.x.com/eicqpcbcar

Thrilled to see our second manuscript during #AACR2023 now published in Cancer Discovery! Cancer Discovery aacrjournals.org/cancerdiscover… Vivek Subbiah, MD Lars Buschhorn Adam Wahida, MD-PhD Figure credit goes to Emma DrawImpacts

Just published for his talk at the #AACR23 session on the Future of Phase I Clinical Trials— N-Of-1 Trials in Cancer Drug Development, by Vivek Subbiah, MD. bit.ly/3oiCAL3 MD Anderson Cancer Center

⭐️Now fully open access for all, published in Cancer Discovery 👉 "N-of-1 Trials in Cancer Drug Development" AACR Cancer Discovery The current approaches for cancer drug development lag behind an accelerated need in the field for a fast & efficient method for evaluating drugs in the

Ahem. How about getting rid of the 100 eligibility criteria —only Olympic athletes with cancer need apply Since the drugs will be used, if approved, in patients with co-morbidities, maybe such patients should be eligible for the clinical trials.

Thrilled to share that our paper on Pan-KRAS inhibitors is now live nature. Inhibitors prevent activation of WT and a broad range of #KRAS mutants, while sparing HRAS+NRAS. Congrats to collaborators @boehringer and MSKCC. #PrecisionOncology OncoAlert nature.com/articles/s4158…

📢We are hiring 🧑🏽‍🔬👩🏼‍🔬👩🏻‍⚕️ Thanks to the great support of the Else Kröner-Fresenius-Stiftung we are recruiting a technical assistant (f/m/d) for our EValuate project Boutroslab DKFZ Universitätsklinikum Heidelberg NCT Heidelberg 🥹🥳 Please RT! Uni Heidelberg Universitätsmedizin Stadt Heidelberg #EVs #wnt jobs.dkfz.de/de/jobs/145539…

Great pleasure and honor presenting this work at #Senologie2023. Oncologic outcomes for different axillary staging techniques in node positive #breastcancer undergoing neoadjuvant chemo. A joint work of Universitätsklinikum Heidelberg and Klinische Landesregisterstelle Baden-Württemberg

Great job André Pfob!

I can’t stop thinking about that French angelfish Denver Zoo Conservation Alliance getting a CT scan and ultrasound last week to evaluate “buoyancy issues.” Were both exams planned, or did the U/S happen first then a radiologist said “suggest CT correlation”? Should they have gone straight to MRI? /1

🎄🚨 Exciting Christmas Eve news! Just published in Annals of Oncology ESMO - Eur. Oncology 🎁 Delighted to unwrap our small #PrecisionMedicine present to the scientific & clinical trial community - our latest publication, "Liquid Biopsy Response Evaluation Criteria in Solid Tumors